Research Article
IDH Mutations: Genotype-Phenotype Correlation and Prognostic Impact
Table 2
Comparison of histologic distribution, molecular alterations, and prognostic impact between IDH mutated and wild type patients.
| | | | | IDH1 mutated tumors* | IDH2 mutated tumors | IDH wild type tumors |
| | Histologic subtypes | Astrocytic tumors | 448 | 87 | 2 | 359 | | AII | 61 | 43 (2) | 1 | 17 | | AIII | 33 | 17 (4) | 0 | 16 | | GBM | 354 | 27 (1) | 1 | 326 | | Oligodendroglial tumors | 584 | 347 | 22 | 215 | | OII | 243 | 182 (10) | 15 | 46 | | OIII | 220 | 150 (5) | 7 | 63 | | GBMO | 121 | 15 (1) | 0 | 106 | | Mixed tumors | 275 | 176 | 6 | 93 | | OAII | 134 | 92 (6) | 5 | 37 | | OAIII | 141 | 84 (9) | 1 | 56 |
| | Molecular alterations | MGMT promoter methylation | 587 | 195/256 (76.2%) | 172/331 (52.0%) | | EGFR amplification | 1248 | 9/609 (1.5%) | 196/639 (30.7%) | | Complete 10q loss | 1148 | 57/572 (10.0%) | 359/576 (62.3%) | | P16 deletion | 1232 | 63/595 (10.6%) | 203/637 (31.8%) | | TP53 mutation | 396 | 64/178 (35.9%) | 49/218 (22.5%) |
| | Prognostic impact | Overall survival | | | | | | Grade II | 309 | 136.5 | 67.0a | | Grade III | 303 | 136.9 | 20.1b | | Grade IV | 435 | 26.6 | 14.2c | | Progression free survival | | | | | | Grade II | 309 | 41.3 | 28.5d | | Grade III | 303 | 31.9 | 10.4e | | Grade IV | 435 | 10.0 | 8.1f |
|
|
For histologic subtypes, the number in parentheses indicates the number of mutations. ; ; ; .
|
